Skip to main content
Clinical Trials/NCT04363099
NCT04363099
Unknown
Not Applicable

Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.

Maison de Sante Pluridisciplinaire de Creil1 site in 1 country1,000 target enrollmentMarch 1, 2020
ConditionsCovid-19

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Covid-19
Sponsor
Maison de Sante Pluridisciplinaire de Creil
Enrollment
1000
Locations
1
Primary Endpoint
clinical description of covid 19 ambulatory cases.
Last Updated
6 years ago

Overview

Brief Summary

Since December 2019, a new agent, the coronavirus SARS-Cov-2, has spread from China to the rest of the world causing an international epidemic of respiratory diseases called COVID-19. Oise was one of the first clusters in France, with more than 4,000 confirmed cases. A significant proportion (80%) of patients with COVID-19 are ambulatory. However, few data are available for this particular population in France. Thus, few clear recommendations are available.

We propose to conduct a large cohort of observation of suspected or confirmed COVID-19 patients on an ambulatory basis in the Oise region. This observatory will make it possible to describe the epidemiological characteristics and initial management of COVID-19 patients and to identify early severity factors.

Registry
clinicaltrials.gov
Start Date
March 1, 2020
End Date
December 31, 2020
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Maison de Sante Pluridisciplinaire de Creil
Responsible Party
Principal Investigator
Principal Investigator

DIMI Svetlane

Dr

Maison de Sante Pluridisciplinaire de Creil

Eligibility Criteria

Inclusion Criteria

  • patients with covid 19 symptoms
  • patients who had a contact with a person PCR Covid 19+

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

clinical description of covid 19 ambulatory cases.

Time Frame: 3 months

Secondary Outcomes

  • Biological and radiological description of ambulatory cases(3 months)
  • Prevalence of positive cases (PCR and/or serological positive)(3 months)

Study Sites (1)

Loading locations...

Similar Trials